Biologics in General Medicine

1. Introduction: Definition and Classification of Biologics
W. -H. Boehncke, H. H. Radeke

Part I. Development and Pre-clinical Pharmacology of Biologics

2. Infliximab: From the Idea to the Product
M. Wiekowski, Ch. E. Antoni

3. Adalimumab
J. Salfeld, H. Kupper

4. Etanercept
Ch. T. Molta

5. Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development
S. Jahn, K. Schmitt-Rau

6. Monoclonal Antibody Targeted Radiation Cancer Therapy
L. M. M. Keller, C. A. Boswell, D. E. Milenic, E. D. Brady, M. W. Brechbiel

7. The Production of Biopharmaceuticals
B. Hughes, L. E. Hann

Part II. Disease-Specific Applications and Clinical Trials

8. Treating Autoimmune Bullous Skin Disorders with Biologics
R. Eming, A. Niedermeier, M. Pfütze, A. Jacobi, M. Hertl

9. Biologics in Psoriasis
W. A. Myers, W. -H. Boehncke, A. B. Gottlieb

10. Biologic Agents in Psoriatic Arthritis
P. Mease

11. Biologic Therapies for Rheumatoid Arthritis Targeting TNF-a and IL-1
P. C. Taylor

12. Biologics in Crohn’s Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonists
J. Salfeld, P. Rutgeerts

13. Multiple Sclerosis: New Immunobiologics
R. Gold, R. Hohlfeld

14. Biologics in Cutaneous Lymphoma
M. Beyer, Ch. Assaf, W. Sterry

15. Biologics in Targeted Cancer Therapy
D. Schrama, J. C. Becker

Part III. Safety and Perspectives

16. Safety Aspects of Biologics: Lessons Learnt from Monoclonal Antibodies
C. K. Schneider, J. Löwer

17. New Biological Therapeutics in the Genome Age
T. N. C. Wells, S. Schnieper-Samec

18. Evidence Based Medicine’s Perspective on Biologics
B. Rzany, A. Nast

DRM-restrictions

Printing: not available
Clipboard copying: not available

Nyckelord: MEDICAL / Public Health MED078000